These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 19095414

  • 1. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany.
    Alba V, Urban E, Angeles Dominguez M, Nagy E, Nord CE, Palacín C, Vila J.
    Int J Antimicrob Agents; 2009 Mar; 33(3):272-5. PubMed ID: 19095414
    [Abstract] [Full Text] [Related]

  • 2. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections.
    Nenoff P, Haustein UF, Hittel N.
    Chemotherapy; 2004 Oct; 50(4):196-201. PubMed ID: 15452398
    [Abstract] [Full Text] [Related]

  • 3. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes.
    Kuwahara K, Kitazawa T, Kitagaki H, Tsukamoto T, Kikuchi M.
    J Dermatol Sci; 2005 Apr; 38(1):47-55. PubMed ID: 15795123
    [Abstract] [Full Text] [Related]

  • 4. [Fundamental studies on antibacterial activity of clindamycin against Propionibacterium acnes].
    Komagata Y, Komiyama K, Nomura S.
    Jpn J Antibiot; 1998 Feb; 51(2):130-6. PubMed ID: 9575439
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
    Yamakawa T, Mitsuyama J, Hayashi K.
    J Antimicrob Chemother; 2002 Mar; 49(3):455-65. PubMed ID: 11864945
    [Abstract] [Full Text] [Related]

  • 6. [Antibacterial activity of nadifloxacin against Staphylococcus and Propionibacterium isolated from patients with dermatological infections].
    Matsuzaki K, Omika K, Hasegawa M, Sato Y, Kobayashi I.
    Jpn J Antibiot; 2006 Aug; 59(4):316-20. PubMed ID: 17111596
    [Abstract] [Full Text] [Related]

  • 7. Bacteriologic profile of the conjunctiva in the patients with dry eye.
    Hori Y, Maeda N, Sakamoto M, Koh S, Inoue T, Tano Y.
    Am J Ophthalmol; 2008 Nov; 146(5):729-34. PubMed ID: 18672220
    [Abstract] [Full Text] [Related]

  • 8. Antimicrobial susceptibility of strains of Propionibacterium acnes isolated from inflammatory acne.
    Gübelin W, Martínez MA, Molina MT, Zapata S, Valenzuela ME.
    Rev Latinoam Microbiol; 2006 Nov; 48(1):14-6. PubMed ID: 17357569
    [Abstract] [Full Text] [Related]

  • 9. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes.
    Oprica C, Nord CE, ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria.
    Clin Microbiol Infect; 2005 Mar; 11(3):204-13. PubMed ID: 15715718
    [Abstract] [Full Text] [Related]

  • 10. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions.
    Nishijima S, Kurokawa I, Katoh N, Watanabe K.
    J Dermatol; 2000 May; 27(5):318-23. PubMed ID: 10875198
    [Abstract] [Full Text] [Related]

  • 11. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris.
    Vogt K, Hermann J, Blume U, Gollnick H, Hahn H, Haustein UF, Orfanos CE.
    Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):943-5. PubMed ID: 1486893
    [Abstract] [Full Text] [Related]

  • 12. Determination of the Mutant Prevention Concentration and the Mutant Selection Window of Topical Antimicrobial Agents against Propionibacterium acnes.
    Nakase K, Nakaminami H, Toda Y, Noguchi N.
    Chemotherapy; 2017 Oct; 62(2):94-99. PubMed ID: 27764829
    [Abstract] [Full Text] [Related]

  • 13. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
    Nishijima S, Nakagawa M, Tsuboi N, Akamatsu H, Horio T, Fujita M, Kawabata S.
    J Int Med Res; 1996 Oct; 24(1):12-6. PubMed ID: 8674789
    [Abstract] [Full Text] [Related]

  • 14. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris.
    Kurokawa I, Nishijima S, Kawabata S.
    Eur J Dermatol; 1999 Oct; 9(1):25-8. PubMed ID: 9920982
    [Abstract] [Full Text] [Related]

  • 15. In vitro activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other antibiotics alone and in combination against Propionibacterium acnes isolates from central nervous system infections.
    Mory F, Fougnot S, Rabaud C, Schuhmacher H, Lozniewski A.
    J Antimicrob Chemother; 2005 Feb; 55(2):265-8. PubMed ID: 15590714
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-5-amino/methylaminopiperidin-1-yl)fluoroquinolone derivatives.
    Zhang Y, Li G, Liu M, You X, Feng L, Lv K, Cao J, Guo H.
    Bioorg Med Chem Lett; 2011 Feb 01; 21(3):928-31. PubMed ID: 21232952
    [Abstract] [Full Text] [Related]

  • 17. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream.
    Plewig G, Holland KT, Nenoff P.
    Eur J Dermatol; 2006 Feb 01; 16(1):48-55. PubMed ID: 16436342
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris.
    Vogt K, Hahn H, Hermann J, Haustein UF, Blume U, Gollnick H, Orfanos CE.
    Drugs; 1995 Feb 01; 49 Suppl 2():266-8. PubMed ID: 8549327
    [No Abstract] [Full Text] [Related]

  • 19. [The rate of inducible clindamycin resistance and susceptibilities to other antimicrobial agents in staphylococci].
    Oğuz VA, Yapar N, Sezak N, Cavuş SA, Kurutepe S, Peksel H, Cakir N, Yüce A.
    Mikrobiyol Bul; 2009 Jan 01; 43(1):37-44. PubMed ID: 19334378
    [Abstract] [Full Text] [Related]

  • 20. Preparation, characterization, and in vitro antimicrobial assessment of nanocarrier based formulation of nadifloxacin for acne treatment.
    Kumar A, Agarwal SP, Ahuja A, Ali J, Choudhry R, Baboota S.
    Pharmazie; 2011 Feb 01; 66(2):111-4. PubMed ID: 21434572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.